Australian biotechnology company, Circadian Technologies announced that its subsidiary company, Vegenics' New Drug Application for its investigative cancer drug has been approved by the US Food and Drug Administration and the company will be conducting clinical trials for the drug.
The company's chief executive Robert Klupacs said that they are finalizing clinical trial sites in the United States and will initiate the clinical trials for the drug, known as VGX-100, by the end of this year with the results expected to be available in the second half of 2012.
Advertisement"We are well advanced in finalising clinical trial sites in the USA and expect clinical trials to commence before the end of 2011 with results becoming available from the study in the second half of 2012", he said, adding that the Phase I trial will involve treating various types of cancer among patients who are in the late stage.
P Shockwave Therapy Could Help Treat Erectile Dysfunction Listening to Mozart Increases Polyp Detection Rate M
You May Also Like